BioNTech
NEWS
On Wednesday, the FDA authorized new Omicron-specific booster shots for Pfizer-BioNTech and Moderna’s COVID-19 vaccines despite a lack of human data.
Moderna announced it is filing lawsuits against Pfizer and BioNTech, alleging that the companies’ COVID-19 vaccine infringes patents covering its mRNA technology.
A day after Pfizer and partner BioNTech submitted an EUA request to the FDA for their booster shot targeting Omicron variants BA.4 and BA.5, the regulator appears close to approving it.
Novavax seeks EUA for COVID-19 Booster, a 100-year-old TB vaccine may protect against the disease and public health officials struggle with fall planning.
Novavax released its second quarter financial results, showing a dramatic adjustment in its sales outlook, while BioNTech prepares to launch two variant-adopted bivalent shots.
August 1 is RNA Day. BioSpace takes a look at recent breakthroughs in RNA therapeutics, and the vast potential of the “vital biological molecule.”
As the second financial quarter of the year comes to a close, pharma and biotech companies are releasing their financial results. For more information on the top-earning companies, read on.
Pfizer and BioNTech initiated a Phase II trial of an enhanced COVID-19 vaccine while fending off lawsuits against CureVac and Alnylam over their technology.
The LPN technology used in the mRNA COVID-19 vaccines has been the target of numerous patent challenges. Here’s a look at recent biopharma patent disputes.
JOBS
IN THE PRESS